1 / 31

NAIC Stock to Study for April 2005 Teva Pharmaceutical Industries Ltd

NAIC Stock to Study for April 2005 Teva Pharmaceutical Industries Ltd. Presented by: Ty Hughes NAIC DC Chapter April 12, 2005. What is NAIC?. National Association of Investors Corporation NAIC teaches individuals how to become successful strategic long-term investors

cathal
Download Presentation

NAIC Stock to Study for April 2005 Teva Pharmaceutical Industries Ltd

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. NAIC Stock to Studyfor April 2005Teva Pharmaceutical Industries Ltd Presented by: Ty Hughes NAIC DC Chapter April 12, 2005

  2. What is NAIC? • National Association of Investors Corporation • NAIC teaches individuals how to become successful strategic long-term investors • NAIC investors use fundamental analysis to study common stocks • Websites: • www.better-investing.org • www.naicdc.org

  3. NAIC Principles • Invest a fixed amount regularly for the long term • Reinvest all of your earnings • Invest only in good quality growth companies • Diversify (25% large companies, 25% small companies, and the rest in between – divided among a variety of industries)

  4. Teva Pharmaceutical Industries • One of the world's largest generic drug companies and has the leading position in the U.S. generic market. • Teva has successfully utilized its production and research capabilities to establish a global pharmaceutical operation focused on supplying the growing demand for generic drugs and on opportunities for proprietary branded products for specific niche categories, with its leading branded drug being Copaxone(R)for multiple sclerosis. • Teva's active pharmaceutical ingredients ("API") business provides both significant revenues and profits from sales to third party manufacturers and strategic benefits to Teva's own pharmaceutical production through its timely delivery of significant raw materials. • During 2004, 64% of its sales in North America, 26% in Europe and 10% in the rest of the world, predominantly in Israel.

  5. American Depositary Receipts • American Depositary Receipts were created in 1927 to aid US investor who wished to purchase shares of non-US corporations. Since that time, ADRs have grown into a popular and flexible structure which enables issuers worldwide to access investor outside their home markets. • An ADR is a negotiable certificate evidencing ownership of shares in a foreign corporation. Each ADR denotes depositary shares which represent a specific number of the underlying shares remaining on deposit in the issuer's home market.

  6. American Depositary Receipts • An American Depositary Receipt (ADR) is a share of stock of an investment in shares of a non-US corporation. The shares of the non-US corporation trade on a non-US exchange, while the ADRs trade on a US exchange. • Two banks are involved in maintaining an ADR: an investment bank and a depositary bank. • The investment bank purchases the foreign shares and offers them for sale in the US. • The depositary bank handles the issuance and cancellation of ADRs certificates backed by ordinary shares based on investor orders, any other services, but is not involved in selling the ADRs.

  7. NAIC Stock Selection Guide • Section 1 – Visual Analysis (sales, EPS and net profit by year, also, high and low price) • Section 2 – Evaluating Management • Section 3 – Price-Earnings History • Section 4 – Evaluating Risk and Reward • Section 5 – Five-Year Potential

  8. Visualizing the Data

  9. Visual Analysis Revenue Hi / LowPrices EPS Net Income

  10. Historic Growth

  11. Projecting Earnings Growth First Call – 20% Visual Analysis – 17% Value Line – 15% Sales, 17% Earnings 16.7% EPS Growth

  12. Preferred Procedure

  13. VL Data for Preferred Procedure 600 Shares Outstanding PTM = .20 / (1 - 0.23) = .2597 or 26%

  14. EPS growth is projected at 15% $1.49 for last FY $1.49 for TTM 5-yr EPS = (1.49)*(1.167)^5 Projected 5-Year EPS Projected5-year EPS is $3.22

  15. Sec. 2: Evaluating Management • Key indicators of management: • Pre-tax profit margin • Return on equity • Compare company’s ratios with its industry • Caution: The worse a company performs, the better value it may appear to be. • Trailing and forward PE drops • Projection at historic growth shows high projected return

  16. Evaluating Management • SSG Section 2 • Pre-tax profit over the past five years of 20.1% with an upward trend • Return on equity over the past five years is 17.9% with a slight downward trend

  17. Trailing Pre-Tax Profit Margin • Pre-tax profit margin sometimes signals a problem before it is reflected in the EPS. No problem here.

  18. Trailing EPS and Revenue Growth

  19. Value Line Quality Indicators • Earnings Predictability—measure of the reliability of an earnings forecast. The most reliable forecasts tend to be those with the highest rating (100); the least reliable (5). • Financial Strength Rating—relative measure of financial strength of the companies reviewed by Value Line. The relative ratings range from A++ (strongest) down to C (weakest), in nine steps.

  20. Financial Strength (B++ or better) Earnings Predictability(85 or better) Value Line Quality Indicators

  21. Confirm Management Quality Robinson Quality Rating 20.0 Fin. Strength13.8 Earnings Pred.12.9 Projected Sales11.8 Projected PTM Total = 58.5

  22. Sec. 3: Price-Earnings History • Accept or amend High and Low avg. PEs • Find 5-yr. high PE, low PE and avg. PE • Look for “signature PE” or range • Relative Value • Current PE / Trailing PE • Current PE / Projected PE • Is PE expansion or contraction likely? • Compare PE to projected growth

  23. Price Earnings History • High PE of 28.5 and Low PE of 17.9 • Average PE of 23.2 • PE trending down • Steady growth often commands a higher PE

  24. Sec. 4: Risk and Reward • Calculate high price in five years • (Avg. High PE) x (Est. 5-yr. EPS) • Calculate low price in five years • (Avg. Low PE) x (Est. 5-yr. low EPS) • Can use current EPS for 5-yr. Low • Find buy, hold & sell zones • Determine upside-downside ratio • Relative value (Current PE / 5-yr avg PE)

  25. Risk and Reward Upside / Downside

  26. Buy – Hold – Sell Range

  27. Sec. 5: Five-Year Potential • Average Total Annual Return • Assumes stock reaches projected high PE in year 5 • Easy to calculate • Compound Total Annual Return* • Assumes stock reaches projected high PE in year 5 • More complex calculation • Projected Average Return* • Assumes stock reaches projected average PE in year 5 • Also a complex calculation * Both Toolkit and Stock Analyst compute these

  28. Five-Year Potential • Return includes 0.7% dividend • Projected Average Return of 16.0% is based on average PE • Total Return of 20.4% is based on average high PE

  29. Teva Conclusions • TEVA is a quality stock. • Value Line financial strength is A but earnings predictability is only 55, RQR is 58.5 • More likely to go up than down • Upside/Downside ratio of 4.3 • Fully priced • Relative value 106.5 < 110 • Estimate Total Return of 20.4% and Projected Average Return of 16.0% (assuming High PE of 24.8)

  30. Conclusion • Email: tyhughes@gmail.com • Materials can be found at:www.tyhughes.net/moosepond Better Investing!

More Related